Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms against Alzheimer's disease and dementia, a review ...

Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Investigating tirzepatide's role in Alzheimer's reveals its potential to improve brain function and reduce inflammation, ...

New research suggests bariatric surgery delivers significantly greater weight loss compared to popular GLP-1 drugs. The study ...

The last year has seen a huge increase in the number of people taking GLP-1 receptor agonists, some prescribed by the NHS and others by private doctors, with common injectibles including semaglutide ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...